2025
Efficacy of beta-blocker agents on clinical outcomes in patients with thoracic aortic aneurysm: A systematic review and meta-analysis of randomized controlled trials
Tanriverdi L, Barrett A, Kalyanasundaram A, Zafar M, Ziganshin B, Elefteriades J. Efficacy of beta-blocker agents on clinical outcomes in patients with thoracic aortic aneurysm: A systematic review and meta-analysis of randomized controlled trials. Vascular Pharmacology 2025, 159: 107494. PMID: 40204023, DOI: 10.1016/j.vph.2025.107494.Peer-Reviewed Original ResearchConceptsThoracic aortic aneurysmRandomized Controlled TrialsPooled risk ratioB-blockersAortic dissectionClinical outcomesAortic aneurysmRisk ratioRisk of aortic dissectionMeta-analysis of randomized controlled trialsControlled TrialsB-blocker treatmentCompared to placeboBeta-blocking agentsCochrane Risk of Bias 2 toolRisk of Bias 2 toolRobust randomized controlled trialsInverse variance-weighted random-effects modelRisk of bias assessmentRandom-effects modelEvidence of benefitSystematic literature searchAortic eventsEvidence-based recommendationsFollow-upCharacterization of studies considered and required under Medicare's coverage with evidence development program.
Mooghali M, Moneer O, Janda G, Ross J, Dhruva S, Ramachandran R. Characterization of studies considered and required under Medicare's coverage with evidence development program. Clinical Trials 2025, 17407745251313979. PMID: 39921418, DOI: 10.1177/17407745251313979.Peer-Reviewed Original ResearchCenters for MedicareMedicare beneficiariesIdentified original research articlesMedicare coverageClinical trial studyEvidence developmentTrial studyQuality of evidenceCoverage decisionsPrimary endpointClinical outcome measuresEvidence of benefitRandomized study designClinical studiesOriginal research articlesDecision MemoMedicaid ServicesOutcome measuresNational Coverage DeterminationMedicareMulti-arm designStudy designDissemination of studiesGoogle ScholarUS patients
2023
Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
Joseph N, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Boise L, Lonial S, Nooka A. Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD). Blood 2023, 142: 647. DOI: 10.1182/blood-2023-187339.Peer-Reviewed Original ResearchStandard-risk patientsHigh-risk patientsOverall response rateRisk patientsPFS benefitInduction therapyHR patientsInduction regimenMyeloma patientsNDMM patientsTransplant-eligible multiple myeloma patientsInternational Myeloma Working Group Uniform Response CriteriaHigh-risk MM patientsEffective induction regimenHigh-risk cytogeneticsCombination of lenalidomideHigh-risk diseaseMultiple myeloma patientsUniform response criteriaDepth of responseLong-term outcomesEvidence of benefitMaintenance therapyOS benefitClinical characteristics
2021
517. Subcutaneous Sarilumab for the Treatment of Hospitalized patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded, Multi-Center Randomized Clinical Trial
Branch-Elliman W, Ferguson R, Doros G, Woods P, Leatherman S, Strymish J, Datta R, Goswami R, Jankowich M, Shah N, Taylor T, Page S, Schiller S, Shannon C, Hau C, Flynn M, Holmberg E, Visnaw K, Dhond R, Brophy M, Monach P. 517. Subcutaneous Sarilumab for the Treatment of Hospitalized patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded, Multi-Center Randomized Clinical Trial. Open Forum Infectious Diseases 2021, 8: 360-360. PMCID: PMC8690689, DOI: 10.1093/ofid/ofab466.716.Peer-Reviewed Original ResearchSubcutaneous sarilumabStandard careMechanical ventilationLearning healthcare systemClinical trialsSevere COVID-19 diseaseCOVID-19Rate of intubationSevere COVID-19Trial of patientsCare clinical trialsIL-6 inhibitionTreatment of patientsNumber of patientsStandard of careHealthcare systemEvidence of benefitCOVID-19 diseaseData monitoring committeeA PragmaticPrimary endpointChart reviewHospitalized patientsPrimary outcomeSupplemental oxygenAssessing the use of low value oncology care following the release of Choosing Wisely guidelines.
Gunn A, Sarver M, Kaplan S, Zafar Y, Greenup R. Assessing the use of low value oncology care following the release of Choosing Wisely guidelines. Journal Of Clinical Oncology 2021, 39: e18861-e18861. DOI: 10.1200/jco.2021.39.15_suppl.e18861.Peer-Reviewed Original ResearchChoosing Wisely guidelinesLow-value careGuideline adherenceSystemic treatmentOncology careCancer screeningValue careASCO Meeting abstractsBest practice alertPatient-reported surveyClaims database analysisCancer care continuumEvidence of benefitPatient-provider conversationsCostly diagnostic testingWeb of SciencePhysician awarenessPractice alertSurveillance imagingCancer careInterventional studyPatient satisfactionEligible studiesPatient anxietyCare continuum
2020
A randomized controlled trial of cognitive behavioral therapy compared with diabetes education for diabetic peripheral neuropathic pain
Higgins DM, Heapy AA, Buta E, LaChappelle KM, Serowik KL, Czlapinski R, Kerns RD. A randomized controlled trial of cognitive behavioral therapy compared with diabetes education for diabetic peripheral neuropathic pain. Journal Of Health Psychology 2020, 27: 649-662. PMID: 33070667, DOI: 10.1177/1359105320962262.Peer-Reviewed Original ResearchConceptsDiabetic peripheral neuropathic painCognitive behavioral therapyPeripheral neuropathic painMental health functioningNeuropathic painPain intensityPain interferenceHealth functioningBehavioral therapyNeuropathic pain intensityOverall pain intensityEvidence of benefitAdjunctive treatmentCBT participantsDiabetes educationPainTherapyTrialsCondition differencesBaselineTreatment of a Large Cohort of Veterans Experiencing Musculoskeletal Disorders with Spinal Cord Stimulation in the Veterans Health Administration: Veteran Characteristics and Outcomes
Wandner LD, Fenton BT, Goulet JL, Carroll CM, Heapy A, Higgins DM, Bair MJ, Sandbrink F, Kerns RD. Treatment of a Large Cohort of Veterans Experiencing Musculoskeletal Disorders with Spinal Cord Stimulation in the Veterans Health Administration: Veteran Characteristics and Outcomes. Journal Of Pain Research 2020, 13: 1687-1697. PMID: 32753944, PMCID: PMC7354010, DOI: 10.2147/jpr.s241567.Peer-Reviewed Original ResearchMusculoskeletal disordersSCS implantsOpioid therapyPain scoresVeterans Health Administration facilitiesSpinal cord stimulator implantationOutcomes of veteransPainful musculoskeletal disordersSpinal cord stimulationVeterans Health AdministrationDepressive disorder diagnosisEvidence of benefitSubstance use disordersPercent of veteransSignificant overall decreaseMSD cohortOpioid doseBMI 25Medical comorbiditiesStimulator implantationChronic painCord stimulationInclusion diagnosisVeteran characteristicsLarge cohortNAM Therapy—Evidence-Based Results
Esenlik E, Gibson T, Kassam S, Sato Y, Garfinkle J, Figueroa A, AlQatami F, Runyan C, Alperovich M, Golinko M, Lee C, Chatzigianni A, Zafeiriadis A, Santiago P, Hosseinian B, Kaygısız E, Üçüncü N, Aslan B, Uzuner F, Gülşen A, Akkurt A, Arslan S, Sabás M, Muñoz-Mendoza M, Masis D, Holguin L, Granados A, Rojas N, Campo B, Keskin K, Akçam M, Lowe K, Morselli P, Pannuto L, Yarza I, Martinez A, Coşkun E, Nissan S. NAM Therapy—Evidence-Based Results. The Cleft Palate-Craniofacial Journal 2020, 57: 529-531. PMID: 31960709, DOI: 10.1177/1055665619899752.Peer-Reviewed Original ResearchConceptsCleft lip and palatePresurgical infant orthopedicsNasoalveolar moldingSurgical outcomesFacial growthSoft tissue facial growthLip and palateImprove surgical outcomesEvidence of benefitInfant orthopedicsOrthodontic interventionMaxillary growthCleft deformitiesPrimary repairSurgical typeTreatment modalitiesRevision surgeryPatientsSurgeryIncreasing burdenPublished studiesOutcomesCleftMinimal interventionDocumented reduction
2019
Use of Mechanical Cardiopulmonary Resuscitation Devices for Out-of-Hospital Cardiac Arrest, 2010-2016
Kahn PA, Dhruva SS, Rhee TG, Ross JS. Use of Mechanical Cardiopulmonary Resuscitation Devices for Out-of-Hospital Cardiac Arrest, 2010-2016. JAMA Network Open 2019, 2: e1913298. PMID: 31617923, PMCID: PMC6806423, DOI: 10.1001/jamanetworkopen.2019.13298.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overBlack or African AmericanCardiopulmonary ResuscitationCross-Sectional StudiesDatabases, FactualEmergency Medical ServicesFemaleHispanic or LatinoHumansIncomeMaleMiddle AgedNew EnglandOut-of-Hospital Cardiac ArrestRetrospective StudiesSex FactorsSuburban Health ServicesWhite PeopleYoung AdultConceptsHospital cardiac arrestMechanical cardiopulmonary resuscitationMechanical CPR deviceAdjusted odds ratioCardiac arrestCardiopulmonary resuscitationManual cardiopulmonary resuscitationCPR deviceOdds ratioNational Emergency Medical Services Information System dataUse of CPRRetrospective cross-sectional studyMechanical cardiopulmonary resuscitation devicesEMS professionalsRisk-standardized ratesPatient demographic characteristicsPrior clinical trialsCross-sectional studyEvidence of benefitCardiopulmonary resuscitation devicesEmergency medical services (EMS) professionalsNortheast census regionMultivariable analysisClinical trialsPrehospital setting
2018
Dietary Long-Chain n-3 Fatty Acid Intake and Arthritis Risk in the Women’s Health Initiative
Krok-Schoen J, Brasky T, Hunt R, Rohan T, Baker T, Li W, Carbone L, Mackey R, Snetselaar L, Lustberg M, Neuhouser M. Dietary Long-Chain n-3 Fatty Acid Intake and Arthritis Risk in the Women’s Health Initiative. Journal Of The Academy Of Nutrition And Dietetics 2018, 118: 2057-2069. PMID: 29921541, PMCID: PMC6204099, DOI: 10.1016/j.jand.2018.04.005.Peer-Reviewed Original ResearchConceptsArthritis riskRA riskPostmenopausal womenWomen's Health Initiative Observational StudyHealth initiativesDietary long chain nClinical trial cohortProspective cohort studyFood frequency questionnairePrevalence of arthritisFatty acid intakeWomen's Health InitiativeCox regression modelAnti-inflammatory propertiesFatty acidsHistory of arthritisEvidence of benefitRheumatoid arthritis riskLong chain nArthritis outcomesCohort studyFrequency questionnaireHazard ratioIncident osteoarthritisTrial cohortAssociation Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non–Small Cell Lung Cancer
Wang EH, Corso CD, Park HS, Chen AB, Wilson LD, Kim AW, Decker RH, Yu JB. Association Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non–Small Cell Lung Cancer. American Journal Of Clinical Oncology 2018, 41: 152-158. PMID: 26523443, DOI: 10.1097/coc.0000000000000245.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedCarcinoma, Non-Small-Cell LungCohort StudiesDatabases, FactualDisease-Free SurvivalDose-Response Relationship, RadiationFemaleHumansLung NeoplasmsMaleMargins of ExcisionMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingPneumonectomyPrognosisProportional Hazards ModelsRadiotherapy DosageRadiotherapy, AdjuvantRadiotherapy, Intensity-ModulatedRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsNon-small cell lung cancerPostoperative radiotherapyCell lung cancerIntensity-modulated radiation therapyPORT doseOverall survivalLung cancerRadiation therapyUse of PORTNational Cancer Data BaseStage IIProportion of patientsGroup of patientsProportional hazards regressionEvidence of benefitSurgical resectionWorse survivalMultivariable analysisHazards regressionRetrospective studyConformal radiationPatientsRadiotherapy techniquesRadiation modalitiesModern treatment
2017
Spiritual Care in the Intensive Care Unit: A Narrative Review
Ho J, Nguyen C, Lopes R, Ezeji-Okoye S, Kuschner W. Spiritual Care in the Intensive Care Unit: A Narrative Review. Journal Of Intensive Care Medicine 2017, 33: 279-287. PMID: 28604159, DOI: 10.1177/0885066617712677.Peer-Reviewed Original ResearchConceptsSpiritual careIntensive care unitPatients' spiritual care needsSpiritual well-being of patientsHigh-quality health careSpiritual care deliverySpiritual care needsFamily members' experiencesSpiritual care resourcesSpiritual care servicesWell-being of patientsHealth-care professionalsHealth-care providersSpiritual Well-BeingPersistent unmet needsCare unitEvidence of benefitIntensive care unit settingCare deliveryCare needsCare servicesHealth careCare resourcesChaplaincy servicesMembers' experiences
2013
STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study
Erickson C, Veenstra-Vanderweele J, Melmed R, McCracken J, Ginsberg L, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter R, Bear M, Wang P, King B. STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study. Journal Of Autism And Developmental Disorders 2013, 44: 958-964. PMID: 24272415, DOI: 10.1007/s10803-013-1963-z.Peer-Reviewed Original ResearchConceptsAutism spectrum disorderSpectrum disorderClinical Global Impression ScaleNon-syndromic autism spectrum disorderExcitatory to inhibitory neurotransmissionGlobal Impression ScaleSocial Responsiveness ScaleGABA-B agonistFragile X syndromeABC-irritabilityImpression ScaleWithdrawal subscalePlacebo-controlled studyAutistic disorderResponse scaleSTX209GABA-BX syndromeOpen-label studyInhibitory neurotransmissionArbaclofenDisordersSubscalesEvidence of benefitOpen-label
2008
Getting By: Underuse of Interpreters by Resident Physicians
Diamond LC, Schenker Y, Curry L, Bradley EH, Fernandez A. Getting By: Underuse of Interpreters by Resident Physicians. Journal Of General Internal Medicine 2008, 24: 256-262. PMID: 19089503, PMCID: PMC2628994, DOI: 10.1007/s11606-008-0875-7.Peer-Reviewed Original ResearchConceptsLimited English proficiencyInterpreter useResident physiciansProfessional interpretersSecond language skillsUrban teaching hospitalEvidence of benefitPhysician-patient communicationResident physician useQuality of careOwn time constraintsValue of communicationEnglish proficiencyLanguage skillsInterpreter servicesTeaching hospitalInterpretersPhysician useClinical decisionStudy institutionPhysiciansDesignQualitative studyRecurrent themesIndividual physiciansUnderuse
2007
Reversal of renal tubule transporter downregulation during severe leptospirosis with antimicrobial therapy.
Spichler A, Ko AI, Silva EF, De Brito T, Silva AM, Athanazio D, Silva C, Seguro A. Reversal of renal tubule transporter downregulation during severe leptospirosis with antimicrobial therapy. American Journal Of Tropical Medicine And Hygiene 2007, 77: 1111-9. PMID: 18165532, DOI: 10.4269/ajtmh.2007.77.1111.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAmpicillinAnimalsAnti-Bacterial AgentsAntigens, BacterialCricetinaeDown-RegulationFemaleFree Radical ScavengersGene Expression ProfilingGene Expression RegulationKidneyLiverMesocricetusSodium-Hydrogen Exchanger 3Sodium-Hydrogen ExchangersSodium-Potassium-Chloride SymportersSolute Carrier Family 12, Member 1ThiobarbituratesWeil DiseaseConceptsSevere leptospirosisAntimicrobial therapyN-acetylcysteineSerum thiobarbituric acidEvidence of benefitThick ascending limbNKCC2 transportersRenal involvementRenal expressionTubular dysfunctionAntioxidant therapyInfected hamstersTubular defectsNAC effectAscending limbAmpicillin treatmentRenal transportersTherapyTarget tissuesLeptospiral antigensAMP treatmentType 3Reduced levelsTransporter downregulationNormal expressionA phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer
Camidge D, Herbst R, Gordon M, Eckhardt S, Kurzroc R, Durbin B, Ing J, Ling J, Sager J, Mendelson D. A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer. Journal Of Clinical Oncology 2007, 25: 3582-3582. DOI: 10.1200/jco.2007.25.18_suppl.3582.Peer-Reviewed Original ResearchTreatment-refractory solid tumorsPhase I safetyColorectal cancer patientsPre-clinical dataEvidence of benefitDR5 agonist antibodyAnti-cancer efficacyIgG1 monoclonal antibodyAsymptomatic transaminitisCohort expansionECOG PSHAHA responseUnacceptable toxicityI safetyObjective responseSymptomatic improvementAdvanced cancerCancer patientsMinor responseReceptor agonistTarget lesionsApomabDisease progressionEfficacy dataPreclinical models
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply